Table 1. Characteristics of the patients in this study.
| No. (%) | Responders | Non-responders | |
|---|---|---|---|
| No. of patients |
43 |
21 |
22 |
|
Age | |||
| Median | 81 | 78 | 80 |
| Range |
52–92 |
64–92 |
52–84 |
| Metastatic disease |
39 (91) |
|
|
|
ECOG performance status | |||
| 0 | 19 (44) | 9 | 10 |
| 1 | 21 (49) | 11 | 10 |
| 2 |
3 (7) |
1 |
2 |
|
Sites of disease | |||
| Prostate | 33 (77) | 12 | 11 |
| Bone | 35 (81) | 16 | 19 |
| Nodes | 11 (26) | 5 | 6 |
| Lung | 1 (2) | 1 | 0 |
| Liver | 1 (2) | 0 | 1 |
| PSA only |
1 (2) |
0 |
1 |
|
No. of involved organs | |||
| 1 | 6 (14) | 3 | 3 |
| >1 |
36 (84) |
18 |
18 |
| Prior radiotherapy/prostatectomy |
6 (14)/9(21) |
3/4 |
3/5 |
| Prior chemotherapy |
25 (58) |
12 |
13 |
| 1 Line |
12 (28) |
7 |
5 |
| 2 Lines |
8 (19) |
3 |
5 |
| >2 Lines |
5 (12) |
2 |
3 |
| Docetaxel-based chemotherapy |
23 (53) |
13 |
12 |
| Mitoxantrone plus prednisone |
17 (39) |
9 |
8 |
|
Serum PSA | |||
| Median (ng ml–1) | 75.1 | 59 | 100 |
| Range |
4.7–5000 |
12–1400 |
4.7–5000 |
|
Gleason score | |||
| <7 | 5 (12) | 3 | 2 |
| 7–10 | 22 (51) | 10 | 12 |
| Not available |
16 (37) |
8 |
8 |
| Median PFS (months) | 5.26 | 9.66 | 2.3 |
| Median OS (months) | 17.39 | 22.26 | 12.66 |
Abbreviations: ECOG=Eastern Cooperative Oncology Group; OS=overall survival; PFS=progression free survival; PSA=prostate-specific antigen.